Project Grant R21CA303007
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$433K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This $463,375 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to identify and characterize the role of melanin-carbonyl-DNA (MCD) and melanin-carbonyl-protein (MCP) adducts in the progression and treatment resistance of NRAS mutant melanoma. The key objectives are to...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic is focused on understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The $635,946 award, with a performance period from July 2024 to June 2029, will support research using an autochthonous mouse melanoma model to investigate how UV radiation-induced interferon-I signaling and tumor inflammatory memory...
This Project Grant award of $223,176 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to define the role of stress granules in cancer initiation. The primary awardee, The Children's Hospital Corporation doing business as Boston Children's Hospital, will leverage a humanized zebrafish melanoma model to investigate how stress granules formed in melanoma precursor cells impact tumor development and progression. The research aims to elucidate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to conduct research on melanoma bone metastasis. The goal is to better understand how melanoma cells infiltrate the bone microenvironment and interact with the immune system, in order to develop improved treatments for melanoma patients with bone metastases. The 2-year project will utilize preclinical murine models to examine the role...
This $122,577 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research to develop and characterize self-amplifying RNA lipid nanoparticles for gene delivery to solid tumors. The primary aims are to: 1) Screen and optimize the self-amplifying RNA and lipid nanoparticle formulation for efficient gene delivery across multiple tumor types, using a gene drive cassette to selectively express a suicide gene in tumors; and 2) Maximize the...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $155,500.00 to The University of Iowa to establish an in-vivo Sleeping Beauty screen to identify and characterize novel drivers of melanomagenesis in a nevi-prone zebrafish model. The goal is to uncover transcriptional mechanisms underlying nevus transformation to melanoma, which could offer critical insights into melanoma biology and advance genetic methodologies in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...